Main Outcomes and Measures
stroke, bleeding, cardiac death, Thrombosis
BLEEDING, MYOCARDIAL INFARCTION, STROKE, CARDIAC DEATH, THROMBOSIS, EVENTS
The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up.